title: Metabolic effect at six and twelve months of cyproterone acetate (2 mg) combined with ethinyl estradiol (35 micrograms) in 31 patients.
abstract: The metabolic effects of cyproterone acetate (2 mg) combined with a new dose level of ethinyl estradiol (35 micrograms) were studied over a one-year period in 31 patients presenting moderate clinical hyperandrogenism. The following tests were performed before treatment, at 6 and 12 months, an oral glucose tolerance test (OGTT) with measurement of insulinemia, total cholesterol, HDL cholesterol and the LDL + VLDL/HDL ratio, A1 and B apoproteins. At six months and at one year of treatment, the weight and body mass index (kg/m2) were not modified. Glucose tolerance and insulinemia had not changed significantly at one year. Lipid test results showed an increase in triglycerides, as well as in total and HDL cholesterol levels. However, the LDL + VLDL/HDL and A1/B apoprotein ratios did not change during the study. We conclude from these results that the new combination does not have any adverse effects on glucose tolerance and has a predominantly estrogenic effect on lipid parameters, characterized by increases in total cholesterol, HDL cholesterol and triglycerides.
authors: Endocrinology and Diabetology Department, Hôpital Saint Louis, Paris, France.
authors: P
authors: P
authors: Vexiau
authors: D
authors: D
authors: Vexiau-Robert
authors: I
authors: I
authors: Martineau
authors: N
authors: N
authors: Hardy
authors: J M
authors: JM
authors: Villette
authors: J
authors: J
authors: Fiet
authors: G
authors: G
authors: Cathelineau
mesh_terms: D000293:Adolescent; D000328:Adult; D000728:Androgens / Q000378:metabolism*; D015113:Androstane-3,17-diol / Q000652:urine; D001054:Apolipoproteins A / Q000097:blood; D001055:Apolipoproteins B / Q000097:blood; D002784:Cholesterol / Q000097:blood; D008076:Cholesterol, HDL / Q000097:blood; D003534:Cyproterone / Q000008:administration & dosage / Q000009:adverse effects / Q000031:analogs & derivatives* / Q000627:therapeutic use; D017373:Cyproterone Acetate; D004359:Drug Therapy, Combination; D004997:Ethinyl Estradiol / Q000008:administration & dosage* / Q000009:adverse effects / Q000627:therapeutic use; D005260:Female; D005951:Glucose Tolerance Test; D006801:Humans; D007328:Insulin / Q000097:blood; D008074:Lipoproteins / Q000097:blood; D014280:Triglycerides / Q000097:blood
chemical_list: D000728:Androgens; D001054:Apolipoproteins A; D001055:Apolipoproteins B; D008076:Cholesterol, HDL; D007328:Insulin; D008074:Lipoproteins; D014280:Triglycerides; D015113:Androstane-3,17-diol; D004997:Ethinyl Estradiol; D017373:Cyproterone Acetate; D002784:Cholesterol; D003534:Cyproterone